| Type 1 Diabetes Mellitus |
1 |
1 |
| Preventive Screening |
0 |
0.99 |
| Child |
0 |
0.51 |
| Newborn Screening |
0 |
0.41 |
| Genetics |
0 |
0.38 |
| Newborn |
0 |
0.38 |
| Genomic Medicine |
0 |
0.2 |
| Birth |
0 |
0.13 |
| Pregnancy |
0 |
0.13 |
| Biologic Therapy |
0 |
0.1 |
| Human Leukocyte Antigen |
0 |
0.09 |
| Inborn Errors of Metabolism |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.09 |
| COVID-19 |
0 |
0.08 |
| Antigens |
0 |
0.06 |
| Blood |
0 |
0.06 |
| Clinical Research |
0 |
0.06 |
| Diabetic Ketoacidosis |
0 |
0.06 |
| Disease-Modifying Therapy |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Financial Reimbursement |
0 |
0.06 |
| Hand |
0 |
0.06 |
| Hospital |
0 |
0.06 |
| Immunotherapy |
0 |
0.06 |
| Informed Consent |
0 |
0.06 |
| Insurance |
0 |
0.06 |
| Intravenous |
0 |
0.06 |
| Metabolism |
0 |
0.06 |
| Monoclonal Antibody |
0 |
0.06 |
| Orbit |
0 |
0.06 |
| Pandemic |
0 |
0.06 |
| Postpartum |
0 |
0.06 |
| Washington |
0 |
0.06 |
| Healthcare and Medical Technology |
0 |
0.03 |